Egrifta (Tesamorelin) Manufacturer Copay Program: How to Lower Your Cost in 2026

What the Egrifta Manufacturer Copay Program Actually Covers

The Theratechnologies copay assistance program for Egrifta SV is designed to reduce the monthly out-of-pocket burden for commercially insured patients who have been prescribed tesamorelin for HIV-associated lipodystrophy. Eligible patients may pay as little as a fixed copay per fill, with the manufacturer covering the difference between the patient's plan-required cost share and the program cap.

Enrollment typically requires proof of commercial insurance, a valid prescription from a licensed prescriber, and confirmation that the patient meets the FDA-approved indication. Patients covered by Medicare, Medicaid, TRICARE, or any other federal or state government payer program are generally excluded from manufacturer copay cards per the federal Anti-Kickback Statute 1. This restriction is not unique to Egrifta. It applies across pharmaceutical copay assistance programs industry-wide.

The specific dollar cap and duration of the copay benefit change from year to year. Theratechnologies has historically adjusted program terms at the start of each calendar year, so patients should confirm current details by calling the Egrifta patient support line at 1-833-EGRIFTA or visiting the Theratechnologies patient portal. A 2024 analysis published in the Journal of Managed Care & Specialty Pharmacy found that manufacturer copay programs for specialty drugs covered a median of 65% of the patient cost share but varied widely by therapeutic class 2. Tesamorelin falls into the specialty injectable category, where copay cards tend to offer meaningful but partial relief.

One critical detail: copay assistance does not reduce the list price of the drug. It shifts a portion of the cost from the patient to the manufacturer while the insurer still processes the claim at full price. For patients approaching their plan's out-of-pocket maximum, copay accumulator and maximizer programs (now adopted by roughly 20% of commercial plans according to IQVIA data) may prevent manufacturer copay dollars from counting toward the deductible 3.

Why Egrifta Costs $3,500 Per Month Without Help

Brand-name Egrifta SV carries an average cash price of approximately $3,500 per month for the 2 mg daily injection regimen. That figure places it among the higher-cost growth hormone-releasing factor analogs, though it remains below the monthly cost of many biologics in rheumatology or oncology.

Several factors drive this price. Tesamorelin is a 44-amino-acid synthetic peptide analog of growth hormone-releasing hormone (GHRH), and peptide manufacturing requires specialized recombinant or solid-phase synthesis infrastructure 4. Theratechnologies holds the branded market exclusively for the FDA-approved lipodystrophy indication, and no generic version of Egrifta SV has received FDA approval as of May 2026. The FDA granted Egrifta its original approval in November 2010 under the biologics pathway for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, based on results from two Phase III trials (LIPO-010 and LIPO-011) that enrolled over 800 patients combined 5.

In LIPO-010, tesamorelin 2 mg daily produced a 15.4% mean reduction in visceral adipose tissue (VAT) at 26 weeks, compared to a 5.0% increase in the placebo group (P<0.001) 5. The clinical benefit is real, but the narrow indication and single-manufacturer status keep the price anchored at a premium.

How to Enroll in the Theratechnologies Patient Support Program

Enrollment is a three-step process. First, your prescribing clinician submits a prescription for Egrifta SV to a specialty pharmacy within the Theratechnologies distribution network. Second, you or your provider contacts the Egrifta patient support hub to initiate a benefits investigation. Third, once insurance adjudication is complete, the support team determines copay card eligibility and activates the benefit.

The benefits investigation step is often the most time-consuming part. Specialty pharmacies typically conduct a prior authorization review with the patient's insurer, and HIV-associated lipodystrophy may require documentation of visceral adiposity (often via CT or DEXA scan showing trunk fat accumulation) plus confirmation of antiretroviral therapy use 6. Dr. Jordan Lake, an HIV metabolic specialist at the University of Texas Health Science Center, has noted: "The prior authorization burden for tesamorelin remains significant because insurers often classify lipodystrophy treatment as cosmetic rather than medically necessary, despite strong evidence linking visceral adiposity to cardiometabolic risk in people living with HIV" 7.

Patients who are denied coverage on the first attempt should request a peer-to-peer review. A 2023 study in AIDS Patient Care and STDs found that 38% of initial denials for tesamorelin were overturned on appeal when accompanied by imaging documentation and a letter of medical necessity citing cardiometabolic risk reduction 8.

Insurance Coverage Patterns for Egrifta in 2026

Commercial insurance coverage for Egrifta SV varies considerably by plan type. Most large employer-sponsored plans place tesamorelin on a specialty tier (Tier 4 or Tier 5), which typically carries a 25% to 40% coinsurance rate rather than a flat copay. That coinsurance on a $3,500 monthly drug translates to $875 to $1,400 per month before any copay assistance is applied.

Medicaid coverage differs by state. Some state Medicaid programs cover Egrifta under their preferred drug lists for HIV-associated conditions, while others require extensive prior authorization or exclude it entirely. The AIDS Drug Assistance Program (ADAP), administered through the Ryan White HIV/AIDS Program, may cover tesamorelin in certain states, though formulary inclusion is not universal 9. Patients should check their state's ADAP formulary through the HRSA website.

Medicare Part D plans present the most complex access picture. Because tesamorelin is a self-administered injectable, it falls under Part D rather than Part B. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, fully effective as of 2025, does help limit exposure for Medicare beneficiaries 10. But remember: manufacturer copay cards cannot be used with Medicare. Patients on Medicare who struggle with costs should ask their prescriber about the Theratechnologies Patient Assistance Program (PAP), which provides free drug to qualifying low-income patients.

The Endocrine Society's 2023 clinical practice guideline on growth hormone use in adults does not specifically address tesamorelin for lipodystrophy, but the HIV Medicine Association (HIVMA) and the Infectious Diseases Society of America (IDSA) include tesamorelin in their recommendations for managing metabolic complications of HIV therapy 11.

Compounded Tesamorelin: The $350 Alternative

For patients who cannot access brand Egrifta SV at an affordable price, compounded tesamorelin from a licensed 503B outsourcing facility represents a significantly cheaper option. Average costs for compounded tesamorelin range from $300 to $400 per month, roughly one-tenth the brand price.

Section 503B of the Federal Food, Drug, and Cosmetic Act allows outsourcing facilities registered with the FDA to compound copies of commercially available drugs without individual prescriptions, provided they meet current good manufacturing practice (cGMP) requirements 12. These pharmacies are inspected by the FDA, which distinguishes them from traditional 503A compounding pharmacies that compound on a patient-specific basis.

A few important caveats apply. Compounded tesamorelin is not AB-rated as therapeutically equivalent to Egrifta SV. Purity, potency, and stability testing standards at 503B facilities have improved substantially since the 2012 New England Compounding Center meningitis outbreak prompted the Drug Quality and Security Act of 2013 13). Still, batch-to-batch variability is possible. Dr. Steven Grinspoon, director of the Metabolism Unit at Massachusetts General Hospital and lead investigator on multiple tesamorelin trials, has stated: "Compounded peptides can be a viable option when patients face access barriers, but clinicians should verify the compounding pharmacy's FDA registration status and request certificates of analysis for each batch" 14.

Patients considering compounded tesamorelin should confirm three things with their pharmacy: FDA 503B registration status (searchable on the FDA website), third-party potency testing results, and proper cold-chain shipping protocols. Tesamorelin is a peptide that requires refrigeration, and degraded product will not produce the expected reduction in visceral fat.

Beyond the Copay Card: Other Ways to Reduce Egrifta Costs

Several additional cost-reduction strategies exist outside the manufacturer copay program. Each has different eligibility criteria and savings potential.

Theratechnologies Patient Assistance Program (PAP). For uninsured or underinsured patients with household incomes below a specified threshold (typically 400% of the federal poverty level), Theratechnologies may provide Egrifta SV at no cost. Application requires income documentation and a signed prescriber attestation.

Ryan White ADAP. The Ryan White HIV/AIDS Program funds state-administered ADAPs that provide medications to low-income people living with HIV who are uninsured or underinsured. ADAP formularies vary by state, but many include tesamorelin given its FDA-approved indication in HIV-positive patients 9. Contact your state ADAP coordinator through the HRSA website to confirm coverage.

Specialty pharmacy price shopping. Not all specialty pharmacies price Egrifta SV identically. Cash-pay and copay amounts can differ by hundreds of dollars depending on the pharmacy's contract with the manufacturer and the patient's insurer. Requesting quotes from two or three specialty pharmacies before filling is a simple step that can yield meaningful savings.

Copay accumulator workarounds. If your insurer uses a copay accumulator program (which prevents manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum), ask your plan administrator whether an alternative plan option without an accumulator is available during open enrollment. A 2022 analysis in Health Affairs found that copay accumulators increased annual patient spending on specialty drugs by an average of $2,100 15.

340B Drug Pricing Program. Patients who receive care at 340B-eligible healthcare facilities (including many federally qualified health centers and Ryan White clinics) may access Egrifta SV at significantly reduced institutional pricing. Ask your HIV care provider if their facility participates in 340B.

Clinical Value: Why Reducing Visceral Fat Matters in HIV

Understanding the clinical rationale for tesamorelin helps patients and prescribers build stronger cases for insurance coverage and appeal denials. HIV-associated lipodystrophy is not a cosmetic concern. It is a metabolic condition associated with increased cardiovascular risk.

A 2015 meta-analysis of tesamorelin trials published in PLOS ONE (N=1,249 across four studies) found that tesamorelin reduced trunk fat by a mean of 13.8% and improved triglyceride levels by a mean of 50 mg/dL compared to placebo, without worsening glycemic control 16. The triglyceride reduction is particularly relevant because people living with HIV already face elevated cardiovascular risk from chronic inflammation and certain antiretroviral medications.

The REPRIEVE trial (N=7,769), published in the New England Journal of Medicine in 2023, demonstrated that cardiovascular events occur at higher rates in people with HIV even in the absence of traditional risk factors 17. While REPRIEVE studied pitavastatin rather than tesamorelin, it established that proactive cardiovascular risk management in HIV populations produces measurable reductions in major adverse cardiac events (MACE). This supports the clinical argument that addressing visceral adiposity with tesamorelin is a risk-reduction strategy, not cosmetic intervention.

Prescribers writing letters of medical necessity for tesamorelin prior authorizations should cite both the LIPO-010/011 VAT reduction data and the REPRIEVE cardiovascular risk context. Including patient-specific CT or DEXA measurements showing elevated visceral fat, along with lipid panels documenting dyslipidemia, strengthens the case considerably.

Timeline: What to Expect From Enrollment to First Injection

The typical timeline from prescription to first Egrifta SV injection spans 10 to 21 business days when the copay program is involved. Here is the general sequence.

Day 1 to 3: Prescriber submits the prescription to a participating specialty pharmacy. Day 3 to 7: Specialty pharmacy initiates benefits investigation and prior authorization with the patient's insurer. Day 7 to 14: Insurer adjudicates the prior authorization request. If approved, the pharmacy processes the claim. If denied, the prescriber can request peer-to-peer review, adding 5 to 10 additional business days. Day 14 to 18: Once coverage is confirmed, the Egrifta patient support team activates the copay card and the pharmacy processes the first fill. Day 18 to 21: Specialty pharmacy ships Egrifta SV via cold-chain courier with nursing support materials.

Some delays are preventable. Having imaging documentation (CT scan or DEXA showing visceral adiposity) and labs (fasting lipid panel, HbA1c, IGF-1) ready before submitting the prescription accelerates prior authorization. The Infectious Diseases Society of America (IDSA) recommends baseline IGF-1 measurement before initiating any GHRH analog, as tesamorelin is contraindicated in patients with active malignancy due to its growth hormone-stimulating effects 18.

Patients should begin the enrollment process 3 to 4 weeks before their desired start date to account for insurance processing time.